DUBLIN--(BUSINESS WIRE)--The "Next-Generation Sequencing: Emerging Clinical Applications and Global Markets" report has been added to ResearchAndMarkets.com's offering.
'Next-Generation Sequencing: Emerging Clinical Applications and Global Markets'
Since NGS platforms can sequence an entire genomic region or even an entire genome, a single test can examine hundreds or thousands of clinically important genetic variations. This means that one test can replace multiple conventional single-gene tests, providing an advantage in price and in the amount of precious sample needed for the test itself.
NGS is often more accurate and reliable than existing diagnostics. This can result in better clinical outcomes. For example, NGS can increase the pregnancy success rates in in vitro fertilization applications. Also, in rare genetic diseases, NGS can increase the success rates for determining a molecular diagnosis. The NGS platform enables companies to expand the menu of disorders/diseases over time after initial launch of a test. This strategy has been employed in reproductive health applications, for example, launching a test to initially screen for aneuploidies, and then later expanding the test to include screening for additional genetic variants. These features of NGS platforms provide a solid basis for the use of this technology in the clinic.
The scope of the report includes clinical NGS technologies, applications, industries, initiatives, patents, and companies. The markets for NGS-based diagnostics are given for the years 2020, 2021, 2022, 2023 and 2028. This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing. It then discusses some of the significant research initiatives that impact clinical NGS applications. Liquid biopsy formats are discussed. The main market driving forces are also discussed.
The report examines the markets by test complexity, clinical indication and test purpose. Test complexity refers to the plex level (i.e., the number of genetic markers that can be analyzed within a sample) and coverage (e.g., the extent to which the genome is covered) of the test. Examining the market by test complexity provides valuable insight into which products (e.g., sample preparation, NGS instrument, informatics, etc.) will be in demand in the future.
Industry sectors analyzed include DNA sequencing instruments; long-read sequencing; sequencing informatics; target enrichment; CTC capture and detection; liquid biopsy; cancer screening/early detection; direct-to-consumer testing; and noninvasive prenatal testing. More than 100 companies in the clinical NGS industry are profiled in this report. 41 data tables and 237 additional tables
An overview of the global market for emerging clinical applications of next-generation sequencing
Analysis of global market trends, featuring historical revenue data for 2020 to 2022, estimates for 2023, as well as forecasts for 2028, including projections of compound annual growth rates (CAGRs) through 2028
Evaluation of the current market size and revenue growth prospects, accompanied by a market share analysis by disease indication, test complexity, test purpose, application and geographic region
Discussion of market opportunities for clinical NGS products, clinical applications, industry structure, regulatory scenarios and use of NGS-based diagnostics and technologies
Description of NGS-oriented tests such as non-invasive prenatal testing (NIPT) and pre-implantation genetic testing (PGT), and a discussion of their advantages
Market share analysis of the key companies and a look at their proprietary technologies, strategic alliances and other key market strategies, plus a patent analysis
Estimated Market Value (USD) in 2023
Forecasted Market Value (USD) by 2028
Compound Annual Growth Rate
Chapter 2 Summary and Highlights
Growth Drivers of Clinical NGS
Chapter 4 Technology Background
Genetic Variation and Analysis
Sequencing in Clinical Applications
History of DNA Sequencing
Sanger Sequencing Technology
Mapping to a Reference Sequence
Artificial Intelligence Technologies
Clinical Sequencing Technology Challenges
Chapter 5 Clinical NGS Initiatives and Emerging Technologies
R&D Initiatives and Programs
Access to Treatment and Testing (ACTT)
Access to Comprehensive Genomic Profiling Coalition (ACGP)
Africa Pathogen Genomics Initiative
China Precision Medicine Initiative
Early Cancer Detection Consortium
France Genomic Medicine Plan
Friends of Cancer Research Project Human Immunomics Initiative
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy Program Liquid Biopsies and Imaging for Improved Cancer Care Liquid Biopsy-Based Malignant Tumor Early Screening Technology Research and Development Project Liver Cancer Early Screening Comprehensive Prevention and Control Project Lung Cancer Genomic Screening Project for Individualized Medicine in Asia Medical Genome Initiative
Precision Medicine Initiative
Target ALS Diagnosis Initiative Treehouse Childhood Cancer Initiative
Worldwide Innovative Networking (WIN) Consortium
Cambridge Single-Cell Analysis Core Facility
Mayo Medical Genome Facility
National Center for Single-Cell Biology
Next-Generation Single-Cell Analysis Program
Single-Cell Analysis Core
Population Sequencing Projects
Chapter 6 Clinical NGS Applications
Chapter 7 Clinical NGS Industry
Chapter 8 ESG Development
Chapter 9 Acquisitions and Strategic Alliances
Chapter 10 Clinical NGS Markets
Chapter 12 Company Profiles
Inex Innovate Private Ltd
Jabrehoo Med Tech Co. Ltd.
Micareo Rare Cell Diagnostics
For more information about this report visit https://www.researchandmarkets.com/r/tklgxp
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.